Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Silver Oak Advisory Group Inc.

Silver Oak Advisory Group Inc. reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 13.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 777 shares of the medical research company’s stock after selling 120 shares during the period. Silver Oak Advisory Group Inc.’s holdings in Bio-Rad Laboratories were worth $251,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. ING Groep NV acquired a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $44,000. GAMMA Investing LLC purchased a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $42,000. Bfsg LLC acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth $77,000. Signaturefd LLC raised its position in Bio-Rad Laboratories by 15.8% in the fourth quarter. Signaturefd LLC now owns 352 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 48 shares during the period. Finally, Banque Cantonale Vaudoise lifted its stake in shares of Bio-Rad Laboratories by 25.0% in the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company’s stock valued at $135,000 after purchasing an additional 75 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 1.0 %

Shares of BIO stock traded down $2.79 during trading on Thursday, reaching $275.42. The company’s stock had a trading volume of 164,771 shares, compared to its average volume of 203,243. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $473.50. The stock’s 50-day moving average price is $326.24 and its 200 day moving average price is $318.15. The company has a market capitalization of $7.85 billion, a price-to-earnings ratio of -12.82 and a beta of 0.87. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, topping the consensus estimate of $2.93 by $0.17. The business had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The company’s quarterly revenue was down 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.31 earnings per share. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday. UBS Group upped their price objective on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Finally, Royal Bank of Canada dropped their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a report on Friday, February 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $468.00.

Insider Buying and Selling

In other news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the sale, the executive vice president now owns 6,942 shares of the company’s stock, valued at $2,332,512. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 17.06% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.